Argent BioPharma Limited Australian S.E.

MXC

AU000000MXC6

Pharmaceuticals

Delayed Australian S.E. Other stock markets 01:01:47 2024-06-14 am EDT			5-day change	1st Jan Change
0.3 ^AUD	0.00%		-6.25%	-36.84%

May. 07	Argent BioPharma Reports CFO Appointment	MT
May. 07	Argent BioPharma shares begin trading on OTCQB Venture Market	AN

MGC Pharma receives AUD800,000 funding from Mercer Street

December 28, 2022 at 04:46 am EST

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Secures AUD800,000 in funding under USD10 million convertible securities financing facility agreement signed with Mercer Street Global Opportunity Fund LLC, a fund managed by Mercer Street Capital Partners. Under the terms of the facility, MGC will issue Mercer 586,432 convertible notes with a face value of USD1.0 each. The company said the funding will be used as working capital for "ongoing operations", including its clinical trials programme.

Current stock price: 0.66 pence, down 1.5% in London on Tuesday

12-month change: down 68%

By Harvey Dorset, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about Argent BioPharma Limited

Argent BioPharma Reports CFO Appointment	May. 07	MT
Argent BioPharma shares begin trading on OTCQB Venture Market	May. 07	AN
Argent BioPharma Begins Trading on US OTCQB Venture Market	May. 07	MT
Argent Biopharma Limited Announces the Appointment of Mr. Igor Bluvstein as Chief Financial Officer	May. 07	CI
Argent BioPharma Limited Announces Appointment of Shlomo Sadoun to the Advisory Board	Apr. 15	CI

Chart Argent BioPharma Limited

Duration

Period

More charts

Company Profile

Argent BioPharma Ltd, formerly MGC Pharmaceuticals Ltd, is an Australia-based drug discovery company. The Company is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its investigational medicinal (IMPs) products include CannEpil, CimetrA and CogniCann. CimetrA is a phyto medicine based on natural ingredients from Curcumin and Boswellia serrata, delivered in the nanoparticle delivery system, which is being developed for acute lung injury and acute respiratory distress syndrome (ARDS). CannEpil is a phyto medicine based on phytocannabinoid is being developed for the treatment of refractory epilepsy and cerebral palsy. CogniCann is a phyto medicine based on phytocannabinoids is in investigation stage as a treatment for the symptoms associated with dementia and Alzheimer.

Sector

Pharmaceuticals

Calendar

2024-08-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
ARGENT BIOPHARMA LIMITED	-36.84%	9.02M
DONG-E-E-JIAO CO.,LTD.	+32.81%	5.82B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-25.27%	3.97B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+5.41%	3.31B
TASLY PHARMACEUTICAL GROUP CO., LTD	-21.39%	2.76B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-11.93%	2.26B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+44.07%	1.92B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-17.86%	1.5B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+43.25%	1.48B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-9.38%	1.49B

Alternative Medicine

Argent BioPharma Limited Australian S.E.

Equities

MXC

AU000000MXC6

Pharmaceuticals

MGC Pharma receives AUD800,000 funding from Mercer Street

Latest news about Argent BioPharma Limited

Chart Argent BioPharma Limited

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Alternative Medicine